1. Home
  2. JGH vs ENTA Comparison

JGH vs ENTA Comparison

Compare JGH & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen Global High Income Fund of Beneficial Interest

JGH

Nuveen Global High Income Fund of Beneficial Interest

HOLD

Current Price

$12.62

Market Cap

355.2M

Sector

Finance

ML Signal

HOLD

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$15.12

Market Cap

382.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
JGH
ENTA
Founded
2014
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
355.2M
382.7M
IPO Year
N/A
2012

Fundamental Metrics

Financial Performance
Metric
JGH
ENTA
Price
$12.62
$15.12
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$20.40
AVG Volume (30 Days)
88.4K
230.9K
Earning Date
01-01-0001
05-11-2026
Dividend Yield
9.85%
N/A
EPS Growth
N/A
29.93
EPS
N/A
N/A
Revenue
N/A
$102,814,000.00
Revenue This Year
N/A
$7.76
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
16.48
52 Week Low
$11.80
$6.44
52 Week High
$13.70
$17.15

Technical Indicators

Market Signals
Indicator
JGH
ENTA
Relative Strength Index (RSI) 44.30 67.66
Support Level $12.40 $13.19
Resistance Level $12.92 $15.48
Average True Range (ATR) 0.20 0.78
MACD -0.02 0.33
Stochastic Oscillator 43.10 89.77

Price Performance

Historical Comparison
JGH
ENTA

About JGH Nuveen Global High Income Fund of Beneficial Interest

Nuveen Global High Income Fund operates as a diversified closed-end management investment company. Its investment objective is to provide a high level of current income. The Fund's securities include U.S. high-yield bonds; non-U.S. high-yield bonds from developed and emerging markets; and other income-producing investments such as preferred and convertible securities.

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

Share on Social Networks: